#USA #Carlsbad #Field Medical #PFA #FieldForce PFA

Promising Developments in Cardiac Ablation Technology

Field Medical, Inc. has made significant strides in cardiac ablation technology, unveiling the results of its first human trial, the Field PULSE trial, published in the esteemed journal JACC Clinical Electrophysiology. This trial focuses on high-voltage focal pulsed field ablation (PFA) for treating complex arrhythmias, marking a pivotal shift in electrophysiology.

Key Findings of the Field PULSE Trial

The findings, presented in a late-breaking clinical trial format at HRX Live 2026, demonstrate a remarkable 94.2% pulmonary vein isolation (PVI) durability rate per vein after twelve months. This is attributed to an optimized waveform used in the ablation process.

The trial introduced a new technique referred to as instantaneous ablation, suggesting an innovative workflow characterized by a median ablation time of just 13 minutes, and a minimum recorded time of 7.7 minutes. The study's results underscore not only procedural efficiency but also safety, with no primary safety events reported during the trial period. Furthermore, 80% of the patients remained free from atrial arrhythmias at the twelve-month mark, highlighting the procedure’s effectiveness.

Clinical Significance of the Findings

Dr. Vivek Reddy, a key co-investigator and electrophysiologist at Mount Sinai Health System, emphasized the trial’s results, stating, "Field PULSE demonstrates the feasibility of a truly instantaneous focal PFA. Completing the application in under 200 milliseconds minimizes the need for prolonged catheter stability while allowing flexibility in point-to-point ablation."

This significant finding paves the way for a new standard in the treatment of arrhythmias, offering hope to patients who struggle with existing methodologies that require longer catheter stabilization.

Expanding the Scope of Cardiac Ablation

The versatility of the FieldForce™ PFA system was a noteworthy highlight of the trial. Nearly 49% of participants received ablation treatments beyond pulmonary veins, showcasing the system's adaptability in addressing additional atrial targets effectively. This multi-faceted approach may revolutionize patient care in electrophysiology.

Dr. Mark A. Turco, president and CEO of Field Medical, spoke to the robust architecture of the FieldForce PFA system, stating, "We designed FieldForce to tackle some of the most complex challenges in focal cardiac ablation, starting from the ventricle. Field PULSE illustrates that the same high-voltage focal PFA architecture enables an instantaneous workflow in the atrium."

Future Implications and Developments

The Field PULSE study builds upon Field Medical's previous clinical work in ventricular tachycardia, expanding the horizons of its PFA technology beyond its original application focus. The ongoing research aims to further elucidate the potential of the FieldForce PFA system in various cardiac substrates using a familiar point-to-point approach.

With the results from this study, Field Medical is poised to continue advancing its differentiated PFA platform, enhancing treatment outcomes for both ventricular and atrial arrhythmias. This promising trajectory offers important clinical evidence that could be transformative for future developments in medical technology focused on cardiac health.

Conclusion

Field Medical, Inc.'s Field PULSE trial results signify a groundbreaking milestone in electrophysiological treatments, showcasing improved efficacy and safety in high-voltage focal PFA systems. As the company moves forward, the implications of this study are expected to resonate widely throughout the medical community, paving the way for innovative treatment options that prioritize efficiency, safety, and patient success.

For more information about Field Medical and its technology, please visit fieldmedicalinc.com.